Immunotherapy in lung cancer: A case report and review of the literatureS. Picardo
and indications. By utilizing aspects of the body’s innate immune system, immunotherapy has improved life expectancy and quality of life for patients with several types of cancer. Adoptive cellular therapies, including chimeric antigen receptor T (CAR T) cell therapy, involve the genetic engineering...
cell cancers, and KEYNOTE results showed that Pembrolizumab improved overall survival (OS) and progression-free survival (PFS) in patients with solid tumors and significantly prolonged the life of patients with locally advanced or metastatic non-small cell lung cancer compared to platinum chemotherapy....
Efficacy and safety of different cycles of neoadjuvant immunotherapy in resectable non-small cell lung cancer: A systematic review and meta-analysis There is no standard consensus on the optimal number of cycles of neoadjuvant immunotherapy prior to surgery for patients with locoregionally advanced non...
Oncology is trailblazing the field of engineered cellular therapeutics. This Review discusses the goals of cellular immunotherapy in cancer, key challenges facing the field and strategies to overcome them—paving the way for treatment of other diseases. ...
Lung Cancer 151, 30–38 (2021). Article CAS PubMed Google Scholar Yang, Y. et al. Efficacy and safety of combined brain radiotherapy and immunotherapy in non-small-cell lung cancer with brain metastases: a systematic review and meta-analysis. Clin. Lung Cancer 23, 95–107 (2022). ...
Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet. 2014;383(9928):1561-1571. doi:10.1016/S0140-6736(13)62159-5 PubMedGoogle ScholarCrossref 16. McGuinness LA, Higgins JPT. Risk-of-bias ...
Reducing Lung Cancer Progression With Immunotherapy Rebecca Voelker, MSJ JAMA. 2018;319(13):1314. doi:10.1001/jama.2018.2928 Full Text The FDA has expanded its approval of durvalumab to include treating patients with unresectable stage III non–small cell lung cancer (NSCLC) whose tumors haven’...
& Ung, Y. Immune checkpoint inhibitors for patients with advanced non–small-cell lung cancer: a systematic review. Clin. Lung Cancer 18, 444–459 (2017). CAS PubMed Google Scholar Friedman, C., Proverbs-Singh, T. & Powtow, M. Treatment of the immune-related adverse effects of immune...
There have been major advances in the immunotherapy of cancer in recent years, including the development of T cell engagers — antibodies engineered to redirect T cells to recognize and kill cancer cells — for the treatment of haematological malignancies. However, the field still faces several chal...